Featured Press Releases

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

  • 18 Jul 2024

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the launch of a new sprinkle formulation of...

Chime Biologics Partners with Polpharma Biologics to Advance Global Biosimilar Development

Chime Biologics Partners with Polpharma Biologics to Advance Global Biosimilar Development

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as the First Treatment for Dry Eye Disease Associated with MGD—A Breakthrough in Ophthalmology

  • Novaliq
  • 09 Jul 2025
Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

  • DualityBio
  • 08 Jul 2025
With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

  • Novogene
  • 07 Jul 2025
Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

  • AudioCure
  • 07 Jul 2025
The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

  • Aurobindo Pharma
  • 02 Jul 2025
Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

  • Fresenius Kabi
  • 01 Jul 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
July   2025
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.